Faculty Opinions recommendation of Perineural liposomal bupivacaine is not superior to nonliposomal bupivacaine for peripheral nerve block analgesia.

Author(s):  
Michael J Buys
2014 ◽  
Vol 58 (3) ◽  
pp. 145-146
Author(s):  
Brian M. Ilfeld ◽  
Nisha Malhotra ◽  
Timothy J. Furnish ◽  
Michael C. Donohue ◽  
Sarah J. Madison

Author(s):  
Thomas W Hamilton ◽  
Vassilis Athanassoglou ◽  
Marialena Trivella ◽  
Stephen Mellon ◽  
David Murray ◽  
...  

2018 ◽  
Vol 129 (4) ◽  
pp. 689-699 ◽  
Author(s):  
Lukas Pichler ◽  
Jashvant Poeran ◽  
Nicole Zubizarreta ◽  
Crispiana Cozowicz ◽  
Eric C. Sun ◽  
...  

Abstract Editor’s Perspective What We Already Know about This Topic What This Manuscript Tells Us That Is New Background Although some trials suggest benefits of liposomal bupivacaine, data on real-world use and effectiveness is lacking. This study analyzed the impact of liposomal bupivacaine use (regardless of administration route) on inpatient opioid prescription, resource utilization, and opioid-related complications among patients undergoing total knee arthroplasties with a peripheral nerve block. It was hypothesized that liposomal bupivacaine has limited clinical influence on the studied outcomes. Methods The study included data on 88,830 total knee arthroplasties performed with a peripheral nerve block (Premier Healthcare Database 2013 to 2016). Multilevel multivariable regressions measured associations between use of liposomal bupivacaine and (1) inpatient opioid prescription (extracted from billing) and (2) length of stay, cost of hospitalization, as well as opioid-related complications. To reflect the difference between statistical and clinical significance, a relative change of −15% in outcomes was assumed to be clinically important. Results Overall, liposomal bupivacaine was used in 21.2% (n = 18,817) of patients that underwent a total knee arthroplasty with a peripheral nerve block. Liposomal bupivacaine use was not associated with a clinically meaningful reduction in inpatient opioid prescription (group median, 253 mg of oral morphine equivalents, adjusted effect −9.3% CI −11.1%, −7.5%; P < 0.0001) and length of stay (group median, 3 days, adjusted effect −8.8% CI −10.1%, −7.5%; P < 0.0001) with no effect on cost of hospitalization. Most importantly, liposomal bupivacaine use was not associated with decreased odds for opioid-related complications. Conclusions Liposomal bupivacaine was not associated with a clinically relevant improvement in inpatient opioid prescription, resource utilization, or opioid-related complications in patients who received modern pain management including a peripheral nerve block.


2020 ◽  
Author(s):  
Brian M. Ilfeld ◽  
James C. Eisenach ◽  
Rodney A. Gabriel

The authors provide a comprehensive summary of all randomized, controlled trials (n = 76) involving the clinical administration of liposomal bupivacaine (Exparel; Pacira Pharmaceuticals, USA) to control postoperative pain that are currently published. When infiltrated surgically and compared with unencapsulated bupivacaine or ropivacaine, only 11% of trials (4 of 36) reported a clinically relevant and statistically significant improvement in the primary outcome favoring liposomal bupivacaine. Ninety-two percent of trials (11 of 12) suggested a peripheral nerve block with unencapsulated bupivacaine provides superior analgesia to infiltrated liposomal bupivacaine. Results were mixed for the 16 trials comparing liposomal and unencapsulated bupivacaine, both within peripheral nerve blocks. Overall, of the trials deemed at high risk for bias, 84% (16 of 19) reported statistically significant differences for their primary outcome measure(s) compared with only 14% (4 of 28) of those with a low risk of bias. The preponderance of evidence fails to support the routine use of liposomal bupivacaine over standard local anesthetics.


Author(s):  
Thomas W Hamilton ◽  
Vassilis Athanassoglou ◽  
Marialena Trivella ◽  
Louise H H Strickland ◽  
Stephen Mellon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document